What Cacit D3 Treats: Main Uses and Benefits

The combination of calcium and vitamin D is commonly used across therapeutic domains where additional symptomatic support is needed. The primary therapeutic applications include addressing established combined vitamin D and calcium deficiencies and being used as adjunct therapy alongside specific prescription treatments for osteoporosis.

Cacit D3 is often used in clinical scenarios where tests confirm low mineral levels, and is applied in addressing conditions presenting with systemic or localized discomfort. This may assist with maintaining functional stability often affected by chronic depletion. The product is relevant for managing symptoms related to physical discomfort, such as bone pain or diminished function due to muscle weakness stemming from prolonged mineral insufficiency. This is relevant when supportive symptom management is appropriate.

Quick Fact: Support for Deficiency-Related Discomfort

Cacit D3 is relevant for easing symptoms linked to systemic imbalance, assisting with the long-term management of chronic depletion and supporting general well-being during symptomatic phases.

Eligibility for Cacit D3: Official Regulatory Status

Cacit D3 (Calcium Carbonate and Colecalciferol) is officially intended for use in adults and the elderly for the treatment and prevention of combined calcium and vitamin D deficiency. It is also authorized as an adjunct to specific therapy for osteoporosis in these populations. The regulatory label explicitly states that the product is not intended for use in children.

Absolute Contraindications (Must Not Use)

Use of Cacit D3 is strictly contraindicated for individuals with pre-existing high levels of calcium in the blood (hypercalcaemia) or urine (hypercalciuria), excessive Vitamin D levels (Hypervitaminosis D), or a history of Nephrolithiasis (kidney stones). It is also prohibited for patients with hypersensitivity to any component.

Restrictions and Cautions

The medicine requires caution and close monitoring for patients with impaired renal function and is generally not recommended in cases of severe renal insufficiency. Caution is also required for patients with sarcoidosis or those who are immobilised with osteoporosis, due to an increased risk of hypercalcaemia.

Pregnancy and Breastfeeding

Use is permitted during pregnancy and breastfeeding, provided the daily intake from all sources does not exceed the upper limits specified in the labeling (e.g., 1500 mg calcium and 600 IU vitamin D) for this physiological state.

The official interaction profile for Cacit D3 (Calcium Carbonate and Colecalciferol) is structured around constraints related to the mineral and vitamin components, as documented in government regulatory sources. Co-administration with other high-dose Vitamin D sources or additional calcium supplements is formally contraindicated due to the risk of hypercalcaemia and toxicity.

Documented Interaction Classes

Timing and Absorption Requirements

Pharmacokinetic interaction is the most prevalent pattern, where calcium reduces the absorption of several co-administered medicinal products. This dictates mandatory separation of administration timing for agents such as Tetracycline and Quinolone antibiotics, Bisphosphonates, and Levothyroxine (thyroid hormone). For example, regulatory information specifies that Levothyroxine must be separated by at least four hours from the calcium component. Foods high in Oxalic Acid (e.g., spinach) or Phytic Acid (e.g., whole grains) may also officially decrease calcium absorption.

Population-specific interaction notes include the required regular serum calcium monitoring for elderly patients taking concomitant cardiac glycosides or thiazide diuretics, as specified in the official documentation.

Cacit D3 is a combination that provides calcium carbonate and cholecalciferol (vitamin D3). The calcium carbonate component acts as a readily available source of Ca^2+ ions. Cholecalciferol is hydroxylated in the liver to form 25-hydroxycholecalciferol, which is then further hydroxylated in the kidney to form 1,25-dihydroxycholecalciferol (calcitriol), the active metabolite. Calcitriol acts on the vitamin D receptors (VDR) on intestinal mucosal cells, increasing the synthesis of calbindin, and thereby increasing the absorption of dietary calcium and phosphate. This mechanism regulates osteoblast and osteoclast activity through Ca^2+ and Pi availability and modulates calcium flux required for bone matrix homeostasis, influencing the parathyroid hormone/vitamin D axis.

Administration Guidelines: How to Use Cacit D3

This section outlines the usage instructions for the standard oral combination of elemental Calcium (1000 mg) and Colecalciferol (Vitamin D3, 800 IU to 880 IU).

The standard protocol is defined by the oral route and once-daily frequency, which establishes a consistent, non-titrated approach to resource replacement. This administration structure is clearly defined to ensure the product is correctly prepared (for effervescent forms) and taken with appropriate spacing from other essential medications.

Research Evidence / Overview of Studies for Cacit D3

Evidence for Correcting Combined Deficiency

The primary clinical use of this combination product research examined the approach to documented low levels of both Calcium and Vitamin D. This research typically involved Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews where participants with established deficiencies were monitored over defined time intervals.

These studies examined key blood markers, including the serum concentration of 25-hydroxyvitamin D (which measures vitamin D status) and levels of calcium. The findings generally describe patterns observed in the studies where participants receiving the supplement had measured serum concentrations that increased for both vitamin D and calcium biomarkers. While these short-term findings are documented, the results apply only to the populations studied, and the data show patterns related to the patterns of these biomarker levels over the intermediate-term.

Evidence for Use as Adjunct Therapy in Osteoporosis

The product was evaluated in studies as a complement to specific prescription drug treatments for osteoporosis. This research largely relies on RCTs and subsequent Meta-analyses focused on older patient groups, such as postmenopausal women with osteoporosis.

These trials primarily examined clinical outcomes like the risk and frequency of total fractures (such as hip fractures), along with changes in Bone Mineral Density (BMD), a measure of bone density. Research exploring the change in fracture risk has shown that findings were mixed and varied across studies. Observed patterns related to clinical outcomes like fracture rate changes were generally described primarily in populations with documented low baseline Vitamin D levels.

What Remains Unclear or Inconsistent in the Research

Clinical research has highlighted several areas where certainty remains low or where data are inconsistent. One key limitation is the variability in reported outcomes regarding fracture risk in different cohorts; findings were mixed when comparing institutionalized populations to non-institutionalized adults.

Furthermore, the research contributes to understanding symptom patterns, but comparative evidence is lacking to fully clarify the contribution of the calcium/vitamin D combination compared to other supports used in frail populations. The follow-up durations were limited in many studies focused on functional outcomes, and there is limited information for long-term outcomes that could help contextualize the sustained effects beyond the trial setting.

Common questions about Cacit D3 (FAQ)

Q: What is the purpose of Cacit D3?

According to official product information, Cacit D3 is prescribed to treat calcium and Vitamin D deficiencies, as well as to supplement calcium and Vitamin D in addition to specific treatments for osteoporosis. The combined intake of calcium and Vitamin D (cholecalciferol) is intended to support bone health.

Q: Does Cacit D3 contain gluten or common allergens?

Regulatory documents indicate that Cacit D3 does not contain gluten. While the official documents do not list common allergens like lactose or aspartame in the main ingredients, patients should review the complete list of excipients in the regulatory leaflet for specific allergy concerns.

Q: Is there a specific time of day I should take Cacit D3?

The official product information does not specify a mandatory time of day for taking Cacit D3, focusing instead on the frequency (once daily). Establishing a consistent routine for administration may help with adherence to the treatment. The precise timing for daily administration can be discussed with a healthcare professional to fit the patient's schedule.

Q: Can Cacit D3 be taken with or without food?

Official information states that the tablets should be dissolved in a glass of water and taken with a meal. Taking the supplement with food may help with better absorption of the ingredients. Refer to the specific instructions provided in the patient leaflet regarding administration.

Q: What is cholecalciferol, and why is it in Cacit D3?

Cholecalciferol is the active form of Vitamin D3, which is essential for the body to absorb calcium properly. Regulatory sources confirm that Cacit D3 combines calcium carbonate with cholecalciferol. This combination is included to ensure that the calcium is effectively utilized for bone maintenance and development.

Q: What is the importance of calcium carbonate in this medicine?

Calcium carbonate is the primary source of calcium in Cacit D3, as confirmed by regulatory information. Calcium is a mineral necessary for various bodily functions, including maintaining strong bones and normal muscle function. This ingredient is included to help address dietary calcium deficiencies.

Q: Is Cacit D3 safe for long-term use?

Official product information notes that Cacit D3 may be used as long-term or intermittent treatment, depending on the specific condition being managed. Long-term use generally requires regular monitoring of calcium levels in the blood and urine to ensure safety. The duration of treatment should be determined by a healthcare provider based on the individual's needs.

Storage and Disposal of Cacit D3

Official regulatory labeling dictates specific conditions for storing and discarding Cacit D3 (Calcium Carbonate/Colecalciferol) effervescent granules.

Storage Requirements

Disposal Instructions

Any unused medicinal product or waste material associated with Cacit D3 must be disposed of in accordance with local requirements. This instruction ensures adherence to proper pharmaceutical waste handling protocols for safe environmental disposal.